Navegando por Palavras-chave "Angiogenesis inducing agents"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
    (Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2014-10-01) Ponce, Cesar Cilento; Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]; Ihara, Silvia Saiuli Miki [UNIFESP]; Silva, Maria Regina Regis; Universidade Federal de São Paulo (UNIFESP)
    Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow biopsies from patients with essential thrombocythemia and primary myelofibrosis. Methods: Microvascular density was evaluated by immunohistochemical analysis and the expression of latent TGF-β1 in samples (100 megakaryocytes per bone marrow sample) from 18 essential thrombocythemia and 38 primary myelofibrosis (19 prefibrotic and 19 fibrotic) patients. Six bone marrow donor biopsies were used as controls. Fibrosis in the bone marrow biopsies was evaluated according to the European Consensus. Results: The average fibrosis grade differed between essential thrombocythemia and primary myelofibrosis groups when compared to the control group. Latent TGF-β1 expression differed significantly between the fibrotic primary myelofibrosis (PMF) group and the control group (p-value < 0.01). A high degree of neo-angiogenesis (demonstrated by analysis of CD34 expression) was detected in patients with myelofibrosis. There were correlations between latent TGF-β1 expression and microvascular density (r = 0.45; p-value < 0.0009) and between degree of microvascular density and fibrosis grade (r = 0.80; p-value < 0.0001). Remarkable differences for neo-angiogenesis were not observed between patients with essential thrombocythemia and controls. Conclusion: Angiogenesis participates in the pathogenesis of primary myelofibrosis, in both the prefibrotic and fibrotic stages, while latent TGF-β is differentially expressed only in the prefibrotic stage.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Terapia gênica com VEGF para angiogênese na angina refratária: ensaio clínico fase I/II
    (Sociedade Brasileira de Cirurgia Cardiovascular, 2010-09-01) Kalil, Renato A. K.; Salles, Felipe Borsu De; Giusti, Imarilde Inês; Rodrigues, Clarissa Garcia; Han, Sang Won [UNIFESP]; Sant'anna, Roberto Tofani; Ludwig, Eduardo; Grossman, Gabriel; Prates, Paulo Roberto Lunardi; Sant'anna, João Ricardo Michelin; Teixeira Filho, Guaracy Fernandes; Nardi, Nance Beyer; Nesralla, Ivo Abrahão; Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia; UFCSPA; Universidade Federal de São Paulo (UNIFESP); Instituto de Cardiologia do RS/Fundação Universitária de Cardiologia Laboratório de Cardiologia Molecular e Celular
    OBJECTIVE: Safety, feasibility and early myocardial angiogenic effects evaluation of transthoracic intramyocardial phVEGF165 administration for refractory angina in no option patients. METHODS: Cohort study, in which 13 patients with refractory angina under optimized clinical treatment where included, after cineangiograms had been evaluated and found unfeasible by surgeon and interventional cardiologist. Intramyocardial injections of 5mL solution containing plasmidial VEGF165 where done over the ischemic area of myocardium identified by previous SPECT/Sestamibi scan. Evaluations included a SPECT scan, stress test, Minnesotta QOL questionnaire and NYHA functional class and CCS angina class determinations. RESULTS: There were no deaths or new interventions during the study period. There were no significant variations in SPECT scans, QOL scores and stress tests results during medical treatment in the included patients. After the 3rd post operative month, there was improvement in SPECT segmental scores, SSS (18.38±7.51 vs. 15.31±7.29, P=0.003) and SRS (11.92±7.49 vs. 8.53±6.68, P=0.002). The ischemic area extension, however, had non-significant variation (23.38±13.12% vs. 20.08±13.88%, P=0.1). Stress tests METs varied from 7.66±4.47 pre to 10.29±4.36 METs post-op (P=0.08). QOL score improved from 48.23±18.35 pre to 30.15±20.13 post-op points (P=0.02). NYHA class was 3.15±0.38 pre vs. 1.77±0.83 post-op (P=0.001) and angina CCS class, 3.08±0.64 vs. 1.77±0.83 (P=0.001). CONCLUSIONS: Intramyocardial VEGF165 therapy for refractory angina, in this small trial of no option patients, resulted feasible and safe. Early clinical and scintilographic data showed improvements in symptoms and myocardial perfusion, with regression of ischemia severity in treated areas.